These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 33671944)
1. Transient Neutropenia in Immunocompetent Infants with Respiratory Syncytial Virus Infection. Korematsu T; Koga H Viruses; 2021 Feb; 13(2):. PubMed ID: 33671944 [TBL] [Abstract][Full Text] [Related]
2. Gut and respiratory tract microbiota in children younger than 12 months hospitalized for bronchiolitis compared with healthy children: can we predict the severity and medium-term respiratory outcome? Cabrera-Rubio R; Calvo C; Alcolea S; Bergia M; Atucha J; Pozo F; Casas I; Arroyas M; Collado MC; García-García ML Microbiol Spectr; 2024 Jul; 12(7):e0255623. PubMed ID: 38785596 [TBL] [Abstract][Full Text] [Related]
3. Nasopharyngeal Microbiota, Host Transcriptome, and Disease Severity in Children with Respiratory Syncytial Virus Infection. de Steenhuijsen Piters WA; Heinonen S; Hasrat R; Bunsow E; Smith B; Suarez-Arrabal MC; Chaussabel D; Cohen DM; Sanders EA; Ramilo O; Bogaert D; Mejias A Am J Respir Crit Care Med; 2016 Nov; 194(9):1104-1115. PubMed ID: 27135599 [TBL] [Abstract][Full Text] [Related]
4. Airway microbiome, host immune response and recurrent wheezing in infants with severe respiratory syncytial virus bronchiolitis. Zhang X; Zhang X; Zhang N; Wang X; Sun L; Chen N; Zhao S; He Q Pediatr Allergy Immunol; 2020 Apr; 31(3):281-289. PubMed ID: 31788862 [TBL] [Abstract][Full Text] [Related]
5. Haemophilus is overrepresented in the nasopharynx of infants hospitalized with RSV infection and associated with increased viral load and enhanced mucosal CXCL8 responses. Ederveen THA; Ferwerda G; Ahout IM; Vissers M; de Groot R; Boekhorst J; Timmerman HM; Huynen MA; van Hijum SAFT; de Jonge MI Microbiome; 2018 Jan; 6(1):10. PubMed ID: 29325581 [TBL] [Abstract][Full Text] [Related]
6. Nasopharyngeal Codetection of Haemophilus influenzae and Streptococcus pneumoniae Shapes Respiratory Syncytial Virus Disease Outcomes in Children. Diaz-Diaz A; Bunsow E; Garcia-Maurino C; Moore-Clingenpeel M; Naples J; Juergensen A; Mertz S; Wang H; Leber AL; Gern J; Hall MW; Cohen DM; Ramilo O; Mejias A J Infect Dis; 2022 Mar; 225(5):912-923. PubMed ID: 34543409 [TBL] [Abstract][Full Text] [Related]
7. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712 [TBL] [Abstract][Full Text] [Related]
8. Streptococcus pneumoniae colonization of the nasopharynx is associated with increased severity during respiratory syncytial virus infection in young children. Brealey JC; Chappell KJ; Galbraith S; Fantino E; Gaydon J; Tozer S; Young PR; Holt PG; Sly PD Respirology; 2018 Feb; 23(2):220-227. PubMed ID: 28913912 [TBL] [Abstract][Full Text] [Related]
10. Altered gut microbiota in infants is associated with respiratory syncytial virus disease severity. Harding JN; Siefker D; Vu L; You D; DeVincenzo J; Pierre JF; Cormier SA BMC Microbiol; 2020 Jun; 20(1):140. PubMed ID: 32487019 [TBL] [Abstract][Full Text] [Related]
11. Bacterial colonization dynamics associated with respiratory syncytial virus during early childhood. Brealey JC; Young PR; Sloots TP; Ware RS; Lambert SB; Sly PD; Grimwood K; Chappell KJ Pediatr Pulmonol; 2020 May; 55(5):1237-1245. PubMed ID: 32176838 [TBL] [Abstract][Full Text] [Related]
18. Haemophilus-Dominant Nasopharyngeal Microbiota Is Associated With Delayed Clearance of Respiratory Syncytial Virus in Infants Hospitalized for Bronchiolitis. Mansbach JM; Hasegawa K; Piedra PA; Avadhanula V; Petrosino JF; Sullivan AF; Espinola JA; Camargo CA J Infect Dis; 2019 May; 219(11):1804-1808. PubMed ID: 30590603 [TBL] [Abstract][Full Text] [Related]
19. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Wang EE; Law BJ; Robinson JL; Dobson S; al Jumaah S; Stephens D; Boucher FD; McDonald J; Mitchell I; MacDonald NE Pediatrics; 1997 Mar; 99(3):E9. PubMed ID: 9099774 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M; Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]